Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors
September 19 2018 - 7:05AM
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the
appointment of Philippe Weigerstorfer to the company’s board of
directors.
Weigerstorfer brings extensive pharmaceutical and dermatology
experience to Sonoma’s board with a track record of expanding
businesses around the globe. He began his career in marketing
at Sandoz and Novartis, advancing to marketing and business leader
roles for cardiovascular, dermatology and other global business
units. During this time, he helped develop and launch highly
successful brands such as Lamisil, Apligraf and Elidel.
In 1999, Weigerstorfer joined Galencia Ltd’s executive team
where he led the retail, pre-wholesale, business development and
M&A divisions. Philippe was a key leader in transforming
Galencia from a Swiss-based wholesaler to a player in the
international healthcare market and with the acquisition of
Canada-based Aspreva, in effectively forming Vifor Pharma Ltd in
2008. At Vifor he was responsible for the business
development, licensing and M&A activities while based in
Canada, and then based in Singapore, heading the regional
operations in Asia Pacific as well as in the Middle East, the
Commonwealth of Independent States, Africa, and Latin America.
“We’re excited to add Philippe’s vast pharmaceutical,
dermatology and international experience to our board of
directors,” said Jim Schutz, Sonoma CEO. “We expect his
knowledge of our core strategic dermatology business along with his
broad pharmaceutical experience will be highly valued as we look to
continue our rapid growth.”
Weigerstorfer will replace Russ Harrison who is retiring from
Sonoma’s board of directors after four and a half years of
service.
“We’d like to thank Russ for his contributions to the board as
he helped orchestrate a new strategy for the company, which
included restructuring and refocusing the company to better target
the high-profitable dermatology space. Personally, I’d like to
thank Russ for his many years of mentoring me and his demonstrative
leadership style,” said Schutz.
About Sonoma Pharmaceuticals, Inc.Sonoma
Pharmaceuticals is a specialty pharmaceutical company that develops
and markets solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “expect,” and
“continue,” among others. Forward-looking statements in this press
release are subject to certain risks and uncertainties inherent in
the Company’s business that could cause actual results to vary,
including such risks that regulatory clinical and
guideline developments may change, scientific data may not be
sufficient to meet regulatory standards or receipt of required
regulatory clearances or approvals, clinical results may not
be replicated in actual patient settings, protection offered
by the Company’s patents and patent applications may be
challenged, invalidated or circumvented by its
competitors, the available market
for the Company’s products will not be as large as
expected, the Company’s products will not be able to penetrate
one or more targeted markets, revenues will not be sufficient
to fund further development and clinical studies, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals® is a registered trademark of Sonoma
Pharmaceuticals, Inc. All other trademarks and service marks
are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Bob MillerCFO(925) 787-6218
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Apr 2023 to Apr 2024
